ERNA - CIK 0000748592
Eterna Therapeutics Inc. trades as ERNA. In its fiscal 2024 annual report the company posted revenue of $582.00K, up 755.9% from the prior year and net income of -$14.08M. This page tracks Eterna Therapeutics Inc. through 1,000 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 10 fiscal years Eterna Therapeutics Inc.'s revenue declined from $26.05M to $582.00K, a compound annual decline rate of 31.6%. Net profit margin compressed from -13.1% to -7652.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-20 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-14 |
| SCHEDULE 13G | - | 2026-05-14 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| Annual report to shareholders | ARS | 2026-05-11 |
| Proxy materials | DEFA14A | 2026-05-11 |
The largest companies sharing Eterna Therapeutics Inc.'s SEC industry classification (pharmaceutical preparations).
Eterna Therapeutics Inc. reported revenue of $582.00K for fiscal year 2024, an increase of 755.9% year over year.
In its latest fiscal year Eterna Therapeutics Inc. reported a net loss of $14.08M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.